Page last updated: 2024-11-07

6-propylchromone-2-carboxylic acid

Description Research Excerpts Clinical Trials Roles Classes Pathways Study Profile Bioassays Related Drugs Related Conditions Protein Interactions Research Growth Market Indicators

Description

6-propylchromone-2-carboxylic acid: structure given in first source [Medical Subject Headings (MeSH), National Library of Medicine, extracted Dec-2023]

Cross-References

ID SourceID
PubMed CID132367
MeSH IDM0204406

Synonyms (9)

Synonym
141474-82-0
4h-1-benzopyran-2-carboxylic acid, 4-oxo-6-propyl-
6-propylchromone-2-carboxylic acid
6-n-propylchromone-2-carboxylic acid
pcca
4-oxo-6-propylchromene-2-carboxylic acid
DTXSID30161739
MXCVHSXCXPHOLP-UHFFFAOYSA-N
4-oxo-6-propyl-4h-chromene-2-carboxylic acid

Research Excerpts

Dosage Studied

ExcerptRelevanceReference
" When rabbits were dosed with the racemic metabolite, excretion of the compound was not stereoselective."( Stereoselective aliphatic hydroxylation of 6-n-propylchromone-2-carboxylic acid by female Dutch rabbits.
Caldwell, J; Winter, SM, 1992
)
0.28
" When rats were dosed with the racemic 1'- and 2-hydroxy metabolites; no stereoselective metabolism or excretion was observed."( Stereoselectivity of the aliphatic hydroxylation of 6-n-propylchromone-2-carboxylic acid in rat and guinea pig.
Caldwell, J; Darbyshire, JF, 1993
)
0.29
" While manufactured forms of the drug for pediatric use are available, there are instances when a compounded liquid dosage form is essential to meet unique patient needs."( Stability of Clindamycin Hydrochloride in PCCA Base SuspendIt.
Bostanian, LA; Graves, RA; Ledet, GA; Mandal, TK; Phan, KV; Pramar, YV,
)
0.13
" However, no commercial liquid dosage form of ursodiol exists."( Stability of Compounded Ursodiol Suspensions in PCCA Base, SuspendIt.
Bostanian, LA; Graves, RA; Mandal, TK; Miller, V; Morris, TC; Nguyen, AT; Pramar, YV,
)
0.13
" The dosing schedule of naltrexone hydrochloride in detoxification protocols needs to be flexible to permit precise, customized dose titration for individual patients."( Physicochemical Stability of Compounded Naltrexone Hydrochloride Solutions in PCCA Base SuspendIt.
Bostanian, LA; Graves, RA; Mandal, TK; Morris, TC; Nguyen, AT; Pramar, YV,
)
0.13
"5-mg, 5-mg, and 10-mg amlodipine besylate tablets do not provide the necessary flexibility in dosing needed for treating children."( Physicochemical Stability of Compounded Amlodipine Besylate Suspensions in PCCA Base, SuspendIt.
Bostanian, LA; Graves, RA; Mandal, TK; Morris, TC; Nguyen, AT; Pramar, YV; Swopes, D,
)
0.13
" The dosage regimen of metronidazole needs to be individualized in the treatment of trichomoniasis, in patients with hepatic impairment, and in pediatric as well as geriatric patients."( Physicochemical and Microbiological Stability of Compounded Metronidazole Suspensions in PCCA SuspendIt.
Bostanian, LA; Graves, RA; Le, G; Mandal, TK; Morris, TC; Pramar, YV,
)
0.13
" The oral dosage regimen of hydrocortisone needs to be individualized in the treatment of congenital adrenal hyperplasia, especially in pediatric patients."( Physicochemical and Microbiological Stability of Extemporaneously Compounded Hydrocortisone Oral Suspensions in PCCA Base, SuspendIt.
Bostanian, LA; Graves, RA; Kader, C; Mandal, TK; Morris, TC; Pramar, YV,
)
0.13
" This flexibility is readily achieved using an oral liquid dosage form."( Physicochemical and Microbiological Stability of Amitriptyline Hydrochloride Oral Liquid Dosage Forms in PCCA Base, SuspendIt.
Bostanian, LA; Graves, RA; Kader, C; Mandal, TK; Morris, TC; Pramar, YV,
)
0.13
" This flexibility is readily achieved using an oral liquid dosage form."( Physicochemical and Microbiological Stability of Pyrimethamine in Paraben-free PCCA Base, SuspendIt.
Bostanian, LA; Graves, RA; Kader, C; Mandal, TK; Morris, TC; Pramar, YV,
)
0.13
" This flexibility is readily achieved using an oral liquid dosage form."( Physiochemical and Microbiological Stability of Azathioprine Suspensions in PCCA Base, SuspendIt.
Bostanian, LA; Graves, RA; Kader, C; Mandal, TK; Morris, TC; Pramar, YV,
)
0.13
[information is derived through text-mining from research data collected from National Library of Medicine (NLM), extracted Dec-2023]

Research

Studies (6)

TimeframeStudies, This Drug (%)All Drugs %
pre-19900 (0.00)18.7374
1990's2 (33.33)18.2507
2000's3 (50.00)29.6817
2010's0 (0.00)24.3611
2020's1 (16.67)2.80
[information is prepared from research data collected from National Library of Medicine (NLM), extracted Dec-2023]

Market Indicators

Research Demand Index: 11.68

According to the monthly volume, diversity, and competition of internet searches for this compound, as well the volume and growth of publications, there is estimated to be weak demand-to-supply ratio for research on this compound.

MetricThis Compound (vs All)
Research Demand Index11.68 (24.57)
Research Supply Index2.77 (2.92)
Research Growth Index4.45 (4.65)
Search Engine Demand Index0.00 (26.88)
Search Engine Supply Index0.00 (0.95)

This Compound (11.68)

All Compounds (24.57)

Study Types

Publication TypeThis drug (%)All Drugs (%)
Trials0 (0.00%)5.53%
Reviews6 (40.00%)6.00%
Case Studies0 (0.00%)4.05%
Observational0 (0.00%)0.25%
Other9 (60.00%)84.16%
[information is prepared from research data collected from National Library of Medicine (NLM), extracted Dec-2023]